Z Laron1. 1. Endocrinology and Diabetes Research Unit, WHO Collaborating Center for the Study of Diabetes in Youth, Schneider Children's Medical Center, Tel Aviv University, 14 Kaplan Street, Petah Tikva 49202, Tel Aviv, Israel. laronz@clalit.org.il
Abstract
AIM: To contribute to the debate about whether growth hormone (GH) and insulin-like growth factor 1 (IGF-1) act independently on the growth process. METHODS: To describe growth in human and animal models of isolated IGF-1 deficiency (IGHD), such as in Laron syndrome (LS; primary IGF-1 deficiency and GH resistance) and IGF-1 gene or GH receptor gene knockout (KO) mice. RESULTS: Since the description of LS in 1966, 51 patients were followed, many since infancy. Newborns with LS are shorter (42-47 cm) than healthy babies (49-52 cm), suggesting that IGF-1 has some influence on intrauterine growth. Newborn mice with IGF-1 gene KO are 30% smaller. The postnatal growth rate of patients with LS is very slow, the distance from the lowest normal centile increasing progressively. If untreated, the final height is 100-136 cm for female and 109-138 cm for male patients. They have acromicia, organomicria including the brain, heart, gonads, genitalia, and retardation of skeletal maturation. The availability of biosynthetic IGF-1 since 1988 has enabled it to be administered to children with LS. It accelerated linear growth rates to 8-9 cm in the first year of treatment, compared with 10-12 cm/year during GH treatment of IGHD. The growth rate in following years was 5-6.5 cm/year. CONCLUSION: IGF-1 is an important growth hormone, mediating the protein anabolic and linear growth promoting effect of pituitary GH. It has a GH independent growth stimulating effect, which with respect to cartilage cells is possibly optimised by the synergistic action with GH.
AIM: To contribute to the debate about whether growth hormone (GH) and insulin-like growth factor 1 (IGF-1) act independently on the growth process. METHODS: To describe growth in human and animal models of isolated IGF-1 deficiency (IGHD), such as in Laron syndrome (LS; primary IGF-1 deficiency and GH resistance) and IGF-1 gene or GH receptor gene knockout (KO) mice. RESULTS: Since the description of LS in 1966, 51 patients were followed, many since infancy. Newborns with LS are shorter (42-47 cm) than healthy babies (49-52 cm), suggesting that IGF-1 has some influence on intrauterine growth. Newborn mice with IGF-1 gene KO are 30% smaller. The postnatal growth rate of patients with LS is very slow, the distance from the lowest normal centile increasing progressively. If untreated, the final height is 100-136 cm for female and 109-138 cm for male patients. They have acromicia, organomicria including the brain, heart, gonads, genitalia, and retardation of skeletal maturation. The availability of biosynthetic IGF-1 since 1988 has enabled it to be administered to children with LS. It accelerated linear growth rates to 8-9 cm in the first year of treatment, compared with 10-12 cm/year during GH treatment of IGHD. The growth rate in following years was 5-6.5 cm/year. CONCLUSION:IGF-1 is an important growth hormone, mediating the protein anabolic and linear growth promoting effect of pituitary GH. It has a GH independent growth stimulating effect, which with respect to cartilage cells is possibly optimised by the synergistic action with GH.
Authors: P J Godowski; D W Leung; L R Meacham; J P Galgani; R Hellmiss; R Keret; P S Rotwein; J S Parks; Z Laron; W I Wood Journal: Proc Natl Acad Sci U S A Date: 1989-10 Impact factor: 11.205
Authors: Y Zhou; B C Xu; H G Maheshwari; L He; M Reed; M Lozykowski; S Okada; L Cataldo; K Coschigamo; T E Wagner; G Baumann; J J Kopchick Journal: Proc Natl Acad Sci U S A Date: 1997-11-25 Impact factor: 11.205
Authors: J Guevara-Aguirre; A L Rosenbloom; O Vasconez; V Martinez; S E Gargosky; L Allen; R G Rosenfeld Journal: J Clin Endocrinol Metab Date: 1997-02 Impact factor: 5.958
Authors: Jose Tadeu Stefano; Maria Lucia Correa-Giannella; Cristiane Maria Freitas Ribeiro; Venancio Avancini Ferreira Alves; Paulo Celso Bosco Massarollo; Marcel Cerqueira Cesar Machado; Daniel Giannella-Neto Journal: World J Gastroenterol Date: 2006-06-28 Impact factor: 5.742
Authors: Sarah K McMenamin; James E N Minchin; Tiffany N Gordon; John F Rawls; David M Parichy Journal: Endocrinology Date: 2013-03-01 Impact factor: 4.736
Authors: Rong Yuan; Shirng-Wern Tsaih; Stefka B Petkova; Caralina Marin de Evsikova; Shuqin Xing; Michael A Marion; Molly A Bogue; Kevin D Mills; Luanne L Peters; Carol J Bult; Clifford J Rosen; John P Sundberg; David E Harrison; Gary A Churchill; Beverly Paigen Journal: Aging Cell Date: 2009-04-09 Impact factor: 9.304
Authors: Susan E Olivo-Marston; Stephen D Hursting; Jackie Lavigne; Susan N Perkins; Rami S Maarouf; Shoshana Yakar; Curtis C Harris Journal: Mol Carcinog Date: 2009-12 Impact factor: 4.784